Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2020 | Enhanced risk stratification in pediatric ALL

Anthony Moorman • 10 Nov 2020
BSH 2020
Acute Lymphoblastic Leukemia Leukemia

Anthony Moorman, PhD, Newcastle University, Newcastle, UK, discusses a risk stratification study from the Children’s Oncology Group in acute lymphoblastic leukemia (ALL) patients at BSH 2020. The study, which analysed over 21,000 patients to determine risk factors, including white blood cell count and minimal residual disease, to calculate individual risk scores as continuous variables, will be presented at ASH 2020. Prof. Moorman highlights how the results of this study will influence future clinical trial design. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anthony Moorman

5:23
Redefining low risk high hyperdiploidy in pediatric ALL
Anthony Moorman • 8 Jun 2021
4:31
T-ALL diagnosis: cytogenetics, genomics and risk assessment
Anthony Moorman • 8 Jun 2021
2:44
Impact of genomics in the future of ALL treatment
Anthony Moorman • 8 Jun 2021
5:10
Prognostic factors in adult ALL patients
Anthony Moorman • 10 Nov 2020

Related Videos

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
1:57
The FORUM trials: results of F1 and plans for F2
Christina Peters • 15 Apr 2024
5:28
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals